Abstract
In this double-blind crossover trial, naproxen (750 mg/day) was compared to placebo for the treatment of osteoarthrosis of the hip and knee. Patients were randomly assigned to treatment with either naproxen or placebo for 4 weeks and then to treatment with the alternate agent for a second 4-week period. 8 out of 9 objective and subjective measurements of drug efficacy clearly differentiated naproxen from placebo at highly significant levels (P = 0.0001 to 0.0004). Patient daily check lists of osteoarthrotic symptoms also showed a statistically significant difference between naproxen and placebo therapy. Both physicians and patients, when asked to give a 'final drug preference', showed a significant preference for naproxen over placebo. In general, the incidence of side effects was low and approximately the same for both naproxen and placebo. Laboratory assessments showed little difference between groups. The trial showed naproxen to be an effective and well tolerated drug for the treatment of osteoarthrosis of the hip and knee.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aagaard J. Osteoartrose behandlet med naproksen. Ugeskr Laeger. 1975 Feb 24;137(9):497–500. [PubMed] [Google Scholar]
- Bowers D. E., Dyer H. R., Fosdick W. M., Keller K. E., Rosenberg A. L., Sussman P., Vancil M. E. Naproxen in rheumatoid arthritis. A controlled trial. Ann Intern Med. 1975 Oct;83(4):470–475. doi: 10.7326/0003-4819-83-4-470. [DOI] [PubMed] [Google Scholar]
- CRAIN D. C. Interphalangeal osteoarthritis. JAMA. 1961 Mar 25;175:1049–1053. doi: 10.1001/jama.1961.03040120011003. [DOI] [PubMed] [Google Scholar]
- Cochrane G. M. A double-blind comparison of naproxen with indomethacin in osteoarthritis. Scand J Rheumatol Suppl. 1973;2:89–93. doi: 10.3109/03009747309097105. [DOI] [PubMed] [Google Scholar]
- Ehrlich G. E. Osteoarthritis beginning with inflammation. Definitions and correlations. JAMA. 1975 Apr 14;232(2):157–159. [PubMed] [Google Scholar]
- Helby-Petersen P., Ibfelt H., Rossel I. A double-blind crossover comparison of naproxen and placebo in rheumatoid arthritis. Scand J Rheumatol Suppl. 1973;2:145–149. doi: 10.3109/03009747309097115. [DOI] [PubMed] [Google Scholar]
- Hill H. F., Hill A. G., Mowat A. G., Ansell B. M., Mathews J. A., Seifert M. H., Gumpel J. M., Christie G. A. Naproxen. A new non-hormonal anti-inflammatory agent. Studies in rheumatoid arthritis. Ann Rheum Dis. 1974 Jan;33(1):12–19. doi: 10.1136/ard.33.1.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Huskisson E. C., Woolf D. L., Balme H. W., Scott J., Franklin S. Four new anti-inflammatory drugs: responses and variations. Br Med J. 1976 May 1;1(6017):1048–1049. doi: 10.1136/bmj.1.6017.1048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- KELLGREN J. H., MOORE R. Generalized osteoarthritis and Heberden's nodes. Br Med J. 1952 Jan 26;1(4751):181–187. doi: 10.1136/bmj.1.4751.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Koch G. G. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics. 1972 Jun;28(2):577–584. [PubMed] [Google Scholar]
- LOWMAN E. W. Osteoarthritis. J Am Med Assoc. 1955 Feb 5;157(6):487–488. doi: 10.1001/jama.1955.02950230001001. [DOI] [PubMed] [Google Scholar]
- Lee P., Webb J., Anderson J., Buchanan W. W. Method for assessing therapeutic potential of anti-inflammatory antirheumatic drugs in rheumatoid arthritis. Br Med J. 1973 Jun 23;2(5868):685–688. doi: 10.1136/bmj.2.5868.685. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tanaka S., Ito T., Mori E., Muroga T., Nakajima A. Double-blind study of Naproxen in osteoarthritis of the knee joint. J Rheumatol. 1976 Mar;3(1):27–36. [PubMed] [Google Scholar]